Bendroflumethiazide


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Oedema
Adult: Initially, 5-10 mg in the morning, daily or on alternate days. Maintenance dose: 5-30 mg wkly in divided doses. Max: 20 mg daily.
Child: 1 mth to 2 yr 50-100 mcg/kg/day; >2-12 yr 50-400 mcg/kg/day (max of 10 mg), followed by 50-100 mcg/kg/day, adjusted according to response.

Oral
Suppression of lactation
Adult: 5 mg in the morning and 5 mg at midday for 5 days.

Oral
Hypertension
Adult: 2.5 mg in the morning daily, either alone or in conjunction w/ other antihypertensive. Max: 20 mg daily.
Child: 1 mth to 2 yr 50-100 mcg/kg/day; >2-12 yr 50-400 mcg/kg/day (max of 10 mg), followed by 50-100 mcg/kg/day, adjusted according to response.

Oral
Idiopathic hypercalciuria
Adult: 2.5 mg daily w/ increased fluid intake.
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Cách dùng
May be taken with or without food. May be taken w/ food or milk.
Chống chỉ định
Anuria, severe renal and hepatic impairment, symptomatic hyperuricaemia, Addison's disease. Refractory hypokalaemia, hyponatraemia, and hypercalcaemia.
Thận trọng
Patients w/ electrolyte imbalance, DM, gout, mild to moderate hepatic and renal impairment. May exacerbate SLE. Pregnancy and lactation.
Phản ứng phụ
Electrolyte imbalance, gout, postural hypotension, GI effects, hyperglycaemia, altered plasma lipid concentration, rashes, photosensitivity, blood disorders, pancreatitis, intrahepatic cholestasis.
PO: C (FDA Pregnancy Category C applies to bendroflumethiazide in combination w/ nadolol.)
Quá liều
Symptoms: Anorexia, nausea, vomiting, diarrhoea, diuresis, dehydration, hypotension, dizziness, weakness, muscle cramps, paraesthesia, tetany, GI bleeding, hyponatraemia, hypo- or hyperglycaemia, hypokalaemia and metabolic alkalosis. Management: Initiate emesis or gastric lavage, if appropriate. Symptomatic and supportive treatment including correction of fluid and electrolyte imbalance. Monitor BP.
Tương tác
Increased serum levels of lithium. Increased nephrotoxicity of NSAID. Increased hypokalaemic effect w/ xanthines, beta-agonists, ACTH, corticosteroids, acetazolamide, carbenoxolone and reboxetine. Enhanced neuromuscular blocking effect of non-depolarising muscle relaxants (e.g. tubocurarine). Postural hypotension may be enhanced by barbiturates, opioids and TCA. Increased risk of hyponatraemia w/ carbamazepine, amphotericin and aminoglutethimide. Increased risk of nephrotoxicity and ototoxicity w/ cisplatin. Reduced absorption by colestipol and colestyramine. Increased risk of ventricular arrhythmias w/ pimozide, thioridazine and terfenadine.
Lab Interference
May interfere w/ PBI (protein-bound iodine) and parathyroid function tests.
Tác dụng
Description: Bendroflumethiazide reduces the reabsorption of electrolytes from the renal tubules, thus increasing the excretion of Na and Cl ions and consequently of water. It also reduces the GFR.
Onset: Approx 2 hr.
Duration: 12-18 hr or longer.
Pharmacokinetics:
Absorption: Completely absorbed from the GI tract. Time to peak plasma concentration: Approx 3-6 hr.
Distribution: Highly bound to plasma proteins.
Metabolism: Undergoes fairly extensive metabolism.
Excretion: Via urine (as unchanged drug). Plasma half-life: Approx 3-4 hr.
Bảo quản
Store between 20-25°C. Protect from excessive heat.
Phân loại MIMS
References
Anon. Thiazides General Statement. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com.

Buckingham R (ed). Bendroflumethiazide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/06/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Bendroflumethiazide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 04/06/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Bendroflumethiazide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in